

1 **Molecular mechanisms associated with multiple sclerosis progression, severity**
2 **and phenotype**

3
4 **Authors:** Peter Kosa¹, Keith Lumbar², Jing Wang², C. Jason Liang³, Ruturaj Masvekar¹, Yujin
5 Kim¹, Mihael Varosanec¹, Lori Jennings⁴, Bibiana Bielekova^{1*}

6 **Affiliations:**

7 ¹Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology,
8 National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda,
9 MD, USA.

10 ²Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer
11 Research; Frederick, MD.

12 ³Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National
13 Institutes of Health; Bethesda, MD, USA

14 ⁴Novartis Institutes for Biomedical Research; Cambridge, MA, USA

15

16 *Corresponding author. Email: Bibi.Bielekova@nih.gov

17

18 **Conflict-of-interest statement:** The authors have declared that no conflict of interest exists.

19 **Abstract:**

20 While current treatments of multiple sclerosis (MS) effectively inhibit formation of focal lesions
21 and relapses, most patients experience progression independent of relapse activity (PIRA). To
22 understand PIRA, we analyzed nine prospectively acquired clinical and imaging outcomes in 176
23 relapsing-remitting and 215 progressive MS patients and 45 healthy volunteers, along with
24 matched cellular and >5000 protein data in 1,042 cerebrospinal fluid (CSF) samples. Regressing
25 out physiological aging and sex effects identified MS-related processes. Among these,
26 compartmentalized inflammation and its effector mechanisms such as pyroptosis showed the
27 strongest association with MS severity, irrespective of clinical categorization of patients.
28 However, molecular processes affected localization of CNS injury: patients with predominant
29 brain damage had proportionally higher neuroinflammation, while fibrosis and tissue hypoxia
30 were linked to principal involvement of spinal cord. We did not identify inflammation-unrelated
31 neurodegeneration; instead, CNS-related processes were beneficial, such as synaptogenesis.
32 Machine learning-based CSF biomarker models predicted nine clinical and volumetric imaging
33 outcomes in the independent cohort with accuracy exceeding published MS models.
34 These data show intra-individual diversity of putative disease mechanisms in MS and implicate
35 processes related to compartmentalized neuroinflammation as leading candidate mechanisms of
36 PIRA. Future drug development should include CNS-penetrant anti-inflammatory agents.

37 **INTRODUCTION**

38 It has been difficult to study pathogenic mechanisms of the central nervous system (CNS)
39 diseases in living humans, because they evolve behind the blood-brain barrier (BBB). Instead,
40 understanding of neurological diseases mostly comes from postmortem human pathology studies
41 complemented by animal models.

42 This is exemplified by multiple sclerosis (MS), a polygenic inflammatory and demyelinating
43 disease of the CNS. Perivascular inflammation in acute MS lesions, combined with studies of
44 experimental autoimmune encephalomyelitis (EAE), recognized migration of lymphocytes to
45 CNS tissue as a therapeutic target for stopping new lesion formation. High efficacy of B cell-
46 depleting treatments showed that in MS, in contrast to EAE, B cells are essential for lesion
47 development. This is likely linked to Epstein Barr virus (EBV) infection of B cells as a
48 necessary, but insufficient trigger of MS (1). Because EBV does not infect rodents, EAE could
49 not elucidate this crucial MS biology, showcasing the need for human studies.

50 Although the MS field benefitted greatly from visionary pathologists who performed highly
51 informative observations (2-8), postmortem studies have understandable limitations. By studying
52 CNS tissue once, usually in the final disease stage, pathology studies cannot differentiate disease
53 consequences from its drivers. Additionally, pathology studies cannot examine CNS in its
54 entirety and instead focus on a single disease aspect (e.g., MS lesions) in a limited number of
55 subjects. Integrating such fractionated view into a system-wide understanding of the mutual
56 relationships and the importance of mechanisms causing clinical disability is difficult. Finally,
57 pathology provides this essential molecular information too late to inform therapeutic decisions.
58 Turning the impediment of relative inaccessibility of CNS into a scientific advantage can
59 generate knowledge uniquely complementary to pathology studies. Specifically, by draining

60 CNS interstitial fluid, the cerebrospinal fluid (CSF) contains analytes from all CNS cells,
61 including infiltrating immune cells. CSF can provide longitudinal view of CNS tissue in health
62 and disease. This study capitalizes on the ability of the National Institutes of Health (NIH)
63 intramural research program to recruit patients willing to undergo research lumbar punctures
64 (LP), and to deeply phenotype their disease using novel outcomes that, while enhancing
65 sensitivity and accuracy, retain strong correlations with outcomes used by regulatory agencies
66 for MS drug approval.

67 The study had two major goals: 1. To analyze measurements of thousands of CSF proteins and
68 enumeration of CSF immune cells in MS and controls to identify pathways and upstream
69 regulators that correlate with all measurable aspects of MS phenotype, including progression
70 independent of relapse activity (PIRA). 2. To use machine learning to derive nine CSF
71 biomarker-based models of aforementioned phenotypical aspects of MS that could predict
72 imaging and clinical outcomes with robust statistical significance when applied to CSF samples
73 derived from new cohort of MS patients. If this is possible, our last goal was to use the high
74 correlation of novel outcomes with traditional MS outcomes to compare effect sizes of CSF
75 biomarker-based models of Expanded Disability Status Scale (EDSS) (9), EDSS-based MS
76 severity outcome Age-related MS severity Scale (ARMSS) (10) and traditional cognitive
77 outcome, the Symbol digit modalities test (SDMT) (11) with the published literature.

78 **RESULTS**

79 The study design is described in Figure1, Table 1, and Supplemental Table 1.

80

81 **Development of comprehensive outcomes to measure different aspects of MS**

82 Treatments that inhibit formation of MS lesions by >90% do not stop disability accumulation
83 and are largely ineffective when started after age 54 (12). This suggests that different
84 mechanisms mediate diverse aspects of MS, including PIRA. To investigate this hypothesis, we
85 must first reliably measure diverse disease attributes.

86 Because individual genes and proteins exert small effect sizes on biological processes associated
87 with complex (polygenic) diseases, success of biomarker modeling strategies strongly depends
88 on the accuracy of modeling outcomes. The advantage of traditional MS outcomes, such as
89 EDSS, is their broad use and easy quantification. The disadvantage is a lack of sensitivity (EDSS
90 measures progression in a stepwise manner with an average patient progressing by 1 EDSS point
91 per decade (13)), non-linear behavior, and weak signal to noise ratio (SNR; e.g., compare weak
92 SNR for MRI volumetric outcomes (14) with strong SNR for contrast-enhancing lesions
93 (CELS)). To transcend this problem, we developed and used novel outcomes with enhanced
94 sensitivity, linearity, and SNR, while assuring that the novel outcomes retained strong correlation
95 with traditional outcomes used for regulatory approval of MS drugs. This maximized the
96 likelihood of obtaining reproducible insight from CSF biomarkers, while allowing verification
97 that this insight is relevant for traditional outcomes by recalibrating models in the training cohort
98 and predicting traditional outcomes in the independent validation cohort.

99 Using this strategy, we pursued comprehensive understanding of three main MS characteristics
100 (Figure 2A): 1. *Formation of acute lesions* measured by (CELs) on brain magnetic resonance
101 imaging (MRI). This process is strongly inhibited by MS treatments, peaks within years of MS
102 onset, declining afterwards even in untreated patients (15). 2. *MS progression and cumulative*
103 *CNS damage*: the cumulative volume of MS lesions (i.e., T2 lesion load; T2LL) increases from
104 MS onset and peaks after CELs start declining, remaining relatively stable afterwards. This
105 volumetric stability may be molecularly dynamic, where expansion of lesion edges might be
106 compensated by the collapse of severely damaged lesion center. This hypothesis is supported by
107 observations that loss of CNS tissue (measured as brain and SC atrophy) and accumulation of
108 disability rise throughout MS duration, albeit at different rates for different subjects. 3. *MS*
109 *severity*: these different rates of accumulation of CNS tissue destruction and irreversible
110 disability reflect MS severity. Ideally, MS severity would be measured prospectively as patient-
111 specific progression slopes. Practically, this is impossible because patients in natural history
112 cohorts are treated with different medications and clinical trials are so short that only minority of
113 patients experience sustained disability accumulation. Consequently, MS severity is measured by
114 cross-sectional outcomes that relate MS progression to time, measured either as age or disease
115 duration. Such cross-sectional MS severity outcomes effectively measure past rates of disability
116 accumulation, by differentiating patients of the same age (or same disease duration) who
117 accumulated more or less CNS damage (red-to-green triangles in Figure 2A). Because our goal
118 was to measure MS progression and MS severity as comprehensibly as possible, we also pursued
119 development of outcomes that differentiate brain from SC involvement.

120 Brain damage (BD) outcome was derived as the inverted first principal component of the
121 correlation between normalized brain volume (brain parenchymal fraction; BPFr) and cognitive

122 outcome SDMT (16) (Figure 2B). This limits noise in BPFr and SDMT measurements and yields
123 outcome that progresses linearly in longitudinal testing (Figure 2A, BD insert) while retaining
124 strong correlation with BPFr and SDMT (Pearson r -0.83 and -0.85, respectively, p -value $< 2.2e$ -
125 16).

126 Combinatorial Weight-adjusted Disability Score (CombiWISE) (14), a continuous scale from 0–
127 100, integrates four outcomes (Figure 2C) and measures linear disability accumulation (Figure
128 2A, CombiWISE insert). CombiWISE correlates strongly with EDSS (i.e., Spearman Rho 0.97,
129 p -value $< 2.2e$ -16); Figure 2C, right top panel and Figure 3A) and timed 25-foot walk (T25FW;
130 Spearman Rho 0.88, p -value $< 2.2e$ -16) (Figure 2C, right bottom panel).

131 To isolate SC disability, we used residuals of linear regression of BD and CombiWISE (Figure
132 2D). For any given BD value, subjects with high SC disability will have accumulated more
133 physical disability than subject with low SC disability. SC disability differentiates subjects with
134 low brain and high SC damage (Figure 2D, MRI inserts for patient 1) from those with high brain
135 and low SC involvement (MRI inserts for patient 2).

136 Collectively, T2LL, BD, CombiWISE, and SC disability will allow identification of molecular
137 processes associated with all types of MS progression. We hypothesized that modeling CSF
138 biomarkers against these outcomes will validate CNS processes seen in MS autopsy studies.
139 However, this analysis will not differentiate processes induced by MS from those that may drive
140 CNS destruction.

141 Studying MS severity increases the probability of identifying such causal processes, as it focuses
142 on mechanisms that differentiate slow from fast progressors among subjects of all ages and
143 disability levels. We used residuals of linear regression models between age and three MS
144 progression outcomes (i.e., BD, CombiWISE, and SC disability; Figure 2E) to derive cross-

145 sectional severity outcomes that capture both cognitive and physical disability. We also included
146 MS Disease Severity Scale (MS-DSS (17)), which integrates clinical and MRI outcomes and
147 adjusts for effects of treatments (Figure 2H). MS-DSS correlates with traditional, EDSS-based
148 MS severity outcomes, MS Severity Scale (MSSS; Spearman Rho 0.68, p -value $< 2.2e-16$), and
149 ARMSS (Spearman Rho 0.66, p -value $< 2.2e-16$) (Figure 2H, lower panels). For reference,
150 modeling outcomes are also summarized in Table 2.

151

152 **Molecular mechanisms associated with natural history of MS progression**

153 Correlation matrix (Figure 3A) relates these new, optimized MS progression outcomes to
154 traditional scales of cognitive (i.e., SDMT and Paced Auditory Serial Addition Test [PASAT]
155 (18)) and physical disability (EDSS, Scripps Neurological Rating Scale [SNRS] (19), Instituto de
156 Pesquisa Clinica Evandro Chagas [IPEC] scale (20), and Ambulation Index [AI] (21)). Strong
157 positive correlations demonstrate that CombiWISE successfully captures all traditional measures
158 of physical disability. Observing that BD correlates the strongest with cognitive disability
159 outcomes and brain T2LL, while SC disability does not correlate with cognitive disability
160 outcomes, T2LL or BD, confirmed achievement of stated goal of separating brain from SC
161 damage.

162 Next, to isolate MS-associated biology, we regressed out effects of physiological aging and sex
163 on CSF proteins measured by DNA-aptamers (i.e., SOMAmers) using longitudinal healthy
164 volunteers (HV) CSF data. All subsequent analyses use HV age/sex-adjusted biomarkers.

165 To uncover the biology of MS progression, we identified biomarkers that correlated significantly
166 (after false discovery rate [FDR]-adjustment of p -values) with MS progression outcomes

167 (Supplemental Table 2) and uploaded their correlation coefficients into Ingenuity Pathway
168 Analysis (IPA[®]). IPA[®] contains over 8.5 million instances of manually curated knowledge about
169 relationships between transcripts, proteins and molecular pathways. Figure 3B, left panel
170 contains sum of z -scores and sum of $-\log_{10} p$ -values for pathways significantly associated with at
171 least two progression outcomes. Most pathways have positive z -scores (shown in red), indicating
172 their predicted activation during MS progression. Majority are neuroinflammation-related, such
173 as IL17, GM-CSF, IL13, LTb, and IL6 signaling, dendritic cell (DC) maturation, high mobility
174 group box protein 1 (HMGB1) signaling, Triggering Receptor Expressed on Myeloid Cells 1
175 (TREM1) signaling, phagosome formation, and role of pattern recognition receptors (PRR) in
176 recognition of bacteria and viruses. However, we also identified strong fibrosis signature: hepatic
177 and pulmonary fibrosis, wound healing, cardiac hypertrophy, and regulation of epithelial-
178 mesenchymal transition (EMT) by growth factors such as epidermal growth factor, and by long
179 noncoding RNA (lncRNA) HOTAIR. Hypoxia, reflected by activation of hypoxia inducible
180 factor 1 subunit alpha (HIF1 α), likewise induces EMT. Senescence and thrombin signaling
181 pathways were also activated with MS progression. Finally, neuronal reelin signaling and
182 neurotrophic growth factor (NGF) signaling induced by MS progression likely reflect response
183 of CNS tissue to injury. Two pathways (inhibition of matrix metalloproteinases and PPAR
184 signaling) had negative z -scores, indicating their predicted suppression during MS progression.
185 Our observation that neuroinflammation *increases* during MS progression contradicts the
186 prevailing belief that neuroinflammation *decreases* with MS progression. Therefore, we
187 employed longitudinal samples from untreated MS patients (collected mostly during placebo-
188 controlled secondary progressive MS [SPMS] (22) and primary progressive MS [PPMS] (23)
189 clinical trials) to investigate intra-individual changes of these pathways during MS progression.

190 Because none of these patients experienced exacerbations during this longitudinal follow-up, this
191 cohort allows us to study intrathecal processes that correlate with PIRA.

192 This analysis was consistent with the cross-sectional cohort (Figure 3B, middle panel), even
193 though longitudinal data consisted of pathways'-specific scores at first and last untreated CSFs
194 (see Methods). Figure 3C exemplifies individual longitudinal data for two of these pathways
195 (i.e., pulmonary fibrosis and HIF1 α signaling). Finally, we observed that activation of these
196 pathways also differentiates MS from HV (Figure 3B, last panel).

197 To expand insight into regulators of identified pathways, we leveraged the ability of IPA[®] to
198 integrate CSF biomarkers into predictions of upstream regulators (Figure 3D; molecules directly
199 upstream of measured biomarkers) and causal networks (Figure 3E; molecules several levels
200 upstream of measured biomarkers) that may operate in meninges and CNS parenchyma. This
201 analysis strengthened the conclusion that neuroinflammation increases with MS progression,
202 highlighting the role of TNF, IFN γ , IL1 β , IL4, IL6, IL11, IL20, IL22, and ligands such as
203 lipopolysaccharide (LPS), aryl hydrocarbon (previously linked to MS and EAE (24)), and
204 hydrogen peroxide generated during oxidative stress.

205

206 **Predominant involvement of brain versus SC in MS is linked to different biology**

207 Developing outcomes that separated cognitive disability linked to BD from physical disability
208 originating from SC allowed search for biological underpinnings of these topological differences.
209 Propensity score matching (Figure 4A) identified MS patients with comparable BD, but different
210 physical (CombiWISE) disability. Because SC disability outcome is novel, we formally tested
211 whether it reflects MS-associated SC injury by correlating it with the cross-sectional SC imaging

212 biomarker measured as C1-2 SC area (Figure 4B). Significant negative correlation proved that
213 BD-CombiWISE residuals reflect SC damage and that propensity score-matched groups have
214 vastly different SC atrophy.

215 We used these matched MS patients to identify pathways activated/inhibited in subjects with
216 comparable BD but different SC disability (Figure 4C, left panel) or, analogously, in subjects
217 with comparable SC disability but different BD (Figure 4C, right panel). Both comparisons
218 yielded consistent results: MS patients with proportionally higher SC disability had activated
219 pathways related to fibrosis (FGF signaling, STAT3 pathway, pulmonary fibrosis, the regulation
220 of EMT, HIF1 α , and cardiac hypertrophy); and to CNS response to injury (synaptogenesis,
221 synaptic long-term potentiation). In contrast, patients with proportionally higher BD showed
222 activation of neuroinflammation pathways, especially IL17, p38 MAPK, and innate immune
223 cells such as DCs, natural killer (NK) cells, and macrophages. Pathways activated in one
224 phenotype were generally repressed in the other.

225 As sensitivity analyses, we used all MS subjects to assess significant correlations between CSF
226 biomarkers and the two divergent progression outcomes. The same pathways (Figure 4D) were
227 associated with predominance of BD versus CombiWISE with high statistical significance.

228

229 **Biological mechanisms with stronger association with MS severity than MS progression**

230 Mechanisms induced by MS (i.e., epiphenomena) would be underrepresented at the beginning of
231 MS and overrepresented in older people with longer disease duration, who accumulated more
232 disability. In other words, processes we identified as correlating with MS progression may
233 represent such epiphenomena. Some of these MS-induced mechanisms may still be causal,

234 meaning that once expressed, they may contribute to CNS injury. Such causal processes should,
235 in addition to correlating with MS progression outcomes also correlate with MS severity
236 outcomes.

237 Yet another category of causal mechanisms may drive CNS injury from the earliest stages of MS
238 through entire MS duration: these processes would differentiate fast progressing from slow
239 progressing MS patients across all age/disability levels. In other words, these candidate
240 pathogenic processes would correlate with MS severity outcomes, but not with MS progression
241 outcomes. Thus, to identify candidate disease mechanisms, we searched for biological processes
242 reflected by CSF biomarkers with much stronger correlation with MS severity than MS
243 progression outcomes.

244 Because the MS severity outcomes employed here are novel, we first assessed their correlation
245 with traditional EDSS-based MS severity outcomes (Figure 5A). CombiWISE severity best
246 reflects EDSS-based severity outcomes, achieving especially strong correlation with ARMSS
247 (i.e., Spearman Rho 0.96, R^2 0.86, p-value < 2.2e-16). Weaker correlations of BD severity with
248 MSSS (Spearman Rho 0.46, R^2 0.22, p-value 7.6e-12) and ARMSS (Spearman Rho 0.50, R^2
249 0.24, p-value 7.5e-14) reflects poor sensitivity of EDSS for cognitive disability and highlights
250 added value of BD severity to identify patients with different rates of accumulation of cognitive
251 disability.

252 Next, using the stated rationale we searched for pathways that correlated with multiple MS
253 severity outcomes, while simultaneously correlating stronger with MS severity than MS
254 progression (Figure 5B and Methods). These pathways are shown in Figure 5C, while upstream
255 regulators and causal networks are in Supplemental Table 3.

256 Although the neuroinflammation-related pathways also dominated this analysis, we observed
257 that some selected pathways were new (i.e., not associated with MS progression), such as
258 activation of B cells and plasmablasts/plasma cells by the B cell activation factor [BAFF] and a
259 proliferation-inducing ligand [APRIL] and pathways related to viral infections (i.e., activation of
260 IRF by cytosolic PRRs, influenza-related pathways and pyroptosis). On the side of innate
261 immunity, the new pathways associated with MS severity but not MS progression were
262 production of nitric oxide (NO) and reactive oxygen species (ROS) in macrophages, crosstalk
263 between dendritic cells (DC) and natural killer (NK) cells and lipopolysaccharide (LPS)/IL-1
264 mediated inhibition of retinoid X receptor (RXR).

265 Other neuroinflammatory pathways, such as those linked to Th17 immunity, HMGB1 signaling
266 and Inhibition of Matrix Metalloproteinases (the latter with negative z-score, which predicts
267 beneficial effect on MS severity) represent examples of pathways that were associated with MS
268 progression but passed this analysis as well due to their stronger correlation with MS severity
269 outcomes.

270 Finally, we note that majority of fibrosis-related pathways (except for related wound healing
271 signaling pathway) did not pass our stringent criteria and thus we consider them only associated
272 with MS progression, but not MS severity. We also failed to identify any inflammation-unrelated
273 true neurodegenerative mechanisms in this analysis. In fact, CNS pathways we identified, such
274 as synaptogenesis and netrin signaling had negative z-score, indicating that they are over-
275 represented in MS patients who progress slower. Analogously, Erythropoietin signaling, and
276 Antioxidant action of vitamin C were predicted as beneficial pathways.

277 **Intra-individual heterogeneity and multiplicity of pathways linked to MS severity**

278 Unsupervised clustering of MS severity-related pathways (Figure 5D) separated MS patients into
279 four clusters. Inhibition of matrix metalloproteinases and Erythropoietin signaling, two of the
280 seven “beneficial” pathways for MS severity (blue font in Figure 5D), clustered with
281 neuroinflammation, consistent with their immunoregulatory role (25). Remaining beneficial
282 pathways of compensatory response of CNS tissue clustered together. Age, sex and traditional
283 MS categorization did not influence clustering, confirming that most of the identified candidate
284 causal pathways are common to all ages and disability levels.

285 Because IPA[®] aggregates knowledge from diverse experimental systems and because the relative
286 concentrations of CSF biomarkers were heavily processed, we asked whether these complex
287 analyses reflect tangible processes. Therefore, we assessed correlations between patient-specific
288 pathway activation scores (see Methods) and previously validated biomarkers of MS-related
289 CNS inflammation measured by different assays.

290 Broadly used neuroinflammation biomarkers such as IgG index and sCD27 demonstrated strong
291 correlation with patient-specific activation scores of inflammatory pathways: Figure 5D, lower
292 panels show their correlation with BAFF/APRIL signaling pathway, representing the strongest
293 correlations observed. Additional weaker, but still significant correlations are shown in
294 Supplemental Figure 1. Pyroptosis was the MS severity pathway with the broadest association
295 with previously identified MS biomarkers, including CHI3L1 and SERPINA3.

296 Integrating prospectively acquired flow-cytometry based CSF cellular data with proteomic
297 analysis shows that neuroinflammation associated with MS severity and MS progression is
298 compartmentalized to CNS tissue and meninges, due to the simultaneous decrease in absolute
299 number of B cells, T cells, and NK cells in the CSF of MS patients associated with MS

300 progression (Supplemental Figure 2). This interpretation is supported by observations that no
301 cellular CSF biomarkers correlated with MS progression or severity outcomes (not shown).

302

303 **CSF biomarkers can be integrated into predictive models of clinical and imaging aspects of** 304 **MS**

305 Our final goal was to assemble CSF biomarkers into models aimed to predict all 9 MS outcomes
306 and to compare effect sizes of such models with the published literature.

307 To gain insight into the nature of relationships between CSF biomarkers (i.e., linear versus non-
308 linear) we used different modeling strategies (Figure 6A): the multiple linear regression
309 represented by elastic net (EN) models and random forest (RF) representing tree-based
310 algorithms. Additionally, being concerned that our training cohort could be too small in
311 relationship to the number of predictors, we compared the models from 5,034 SOMAmers with
312 models from 12.9 million SOMAmer ratios. As the models based on SOMAmer ratios had
313 >2500-fold higher numbers of predictors per subject, if our training cohort was of inadequate
314 size for ML algorithms to find optimal solutions, the SOMAmer ratio-based models should have
315 higher degree of overfit, leading to weaker validation.

316 In the training cohort (Figure 6B shown as circles; Supplemental Table 4): the RF models
317 outperformed EN models, even though EN models included more biomarkers (thousands)
318 compared to RF models (up to hundreds). This suggested non-linear relationships in the structure
319 of CSF biomarkers and pathways they represent. Additionally, models from biomarker ratios
320 outperformed models from single SOMAmers. The out-of-bag (OOB) RF results are often used
321 in lieu of validation strategy, as they reflect model's performance on the samples that the

322 algorithm omitted from the specific iteration(s) of the model. Consistently, OOB results (Figure
323 6B; squares) showed diminished effect sizes for all models.

324 However, the OOB results, like all cross-validation strategies that reuse training cohort, contain
325 circular argument (26): these samples did contribute to some aspects of the final models, e.g., the
326 selection of predictors. Therefore, the true effect sizes can be derived only from a new cohort of
327 patients, whose samples did not participate in any aspects of model development (27).

328 When final models were applied to independent validation cohort (Figure 6B diamond shapes), it
329 became obvious that CSF proteins, like previously shown for genes, exert mostly linear
330 (additive/subtractive) effects on clinical outcomes, as EN models validated with comparable or
331 higher effect sizes than RF models (e.g., see SC severity). The models from SOMAmer ratios
332 also validated comparable or higher effect sizes to models from individual SOMAmers, proving
333 that our training cohort was sufficiently large to find optimal solutions.

334 Two observations showcase the necessity to use independent validation for assessing ML-based
335 models: first the effect sizes for all models decreased significantly when compared to OOB data.
336 Second, the OOB data did not predict even the hierarchy of model validation: e.g., the RF SC
337 severity models did not validate, even though their OOB performance strongly outperformed
338 CEL models, which validated with some of the highest effect sizes (Figure 6B; Supplemental
339 Figure 3).

340 The most insightful result from comparing the different modeling strategies is that *the strongest*
341 *determinant of validated effect sizes was the modeling outcome*. While we validated models for
342 all MS outcomes with very low *p*-values, the hierarchy of effect sizes strongly suggest that the
343 limiting factor in model's performance is the outcome: the level of accuracy with which we can
344 measure it and the degree to which it reflects tangible biological processes.

345

346 **CSF-biomarker based models reliably predict traditional MS outcomes in the independent**
347 **validation cohort**

348 Although the hierarchy of validated effect sizes support our premise that we need accurate
349 outcomes to successfully model different MS characteristics; the major drawback of these
350 optimized outcomes is that they are not used broadly. However, based on strong correlations
351 between novel outcomes and traditional MS outcomes (Figures 1-3), we knew we can
352 mathematically recalibrate CSF-biomarker models in training cohort to predict traditional
353 outcomes (Figure 6C).

354 We used CSF-biomarker predicted CombiWISE to derive linear regression model with measured
355 EDSS (Figure 6C, top panel). Applying this correction to the validation cohort (Figure 6C,
356 second panel from the top), we observed correlations between measured and CSF-biomarker
357 predicted EDSS that explained 46% of variance (p-value $<2.2e-16$) with concordance correlation
358 coefficient (CCC)=0.58 (i.e., CCC = 1 represents exact concordance between measured and
359 predicted outcomes). Analogously, predicted ARMSS (Figure 6C, lower two plots) in the
360 independent cohort explained 20% of variance (p-value $1.2e-7$) with CCC=0.38. Finally, we used
361 CSF-predicted BD to derive a linear model with measured SDMT. The model-predicted SDMT
362 in the validation cohort explained 36% of variance (p-value $1.1e-11$) of the measured SDMT
363 with CCC= 0.54 (Supplemental Figure 6).

364 Based on the meta-analysis of MS models (28), these are the strongest validated effect sizes for
365 these 3 traditional outcomes used for regulatory approval of MS drugs, using any type of
366 predictors (i.e., clinical/demographic, MRI, blood/CSF biomarkers or genes).

367 **DISCUSSION**

368 Mechanistic understanding of the MS lesions and their reliable quantification by CELs
369 spearheaded development of treatments that virtually eliminate their formation. This study
370 elucidates processes associated with natural history of MS beyond the formation of MS lesions,
371 including PIRA, which represents currently the most pressing therapeutic need in MS.

372 Because it is impossible to discuss every molecule in this rich dataset, Supplementary Tables
373 contain comprehensive analyses of single protein(s) with all raw data acquired in this study.

374 While we reproduced most studies linking specific protein(s) with MS, single proteins exerted
375 (predictably) much smaller effect sizes on MS outcomes compared to pathways that aggregate
376 proteins based on their biological relationships. Therefore, we focused the results, and we'll
377 focus the discussion on these pathways.

378 The most surprising result of current study is the dominance of neuroinflammation-related
379 pathways among biological processes that correlate with both MS progression and MS severity.

380 As current MS drugs inhibit inflammation and formation of inflammatory CELs, their decreasing
381 efficacy in later stages of MS, characterized by PIRA, led to broad belief that progressive MS
382 (PMS) is *less* inflammatory than relapsing-remitting MS (RRMS) and that neurodegenerative
383 mechanisms drive disability accumulation in PMS (29). In contrast, our results show that
384 intrathecal activation of (some) neuroinflammation-related pathways *increases* with MS
385 progression. This was based on the analysis of CSF biomarkers that correlate with diverse MS
386 progression outcomes and validated by biomarkers that significantly changed in longitudinal
387 CSF samples from placebo arms of PMS clinical trials. Because none of these progressive
388 patients experienced MS relapse during this longitudinal follow-up, they represent PIRA cohort.

389 The second unexpected observation was that our analyses did not identify any inflammation-
390 unrelated neurodegenerative pathways that would positively correlate with MS progression or
391 MS severity. This lack of inflammation-unrelated neurodegenerative mechanisms validates
392 genotyping data that linked expression of genes associated with MS susceptibility alleles to the
393 cells of the immune system (including its intrathecal components such as microglia and
394 astrocytes), but not neurons (30).

395 The third unexpected observation was that inflammatory pathways that correlate with MS
396 progression did not comprise one unique phenotype: they included both innate and adaptive
397 immunity of Th17 (IL17, GM-CSF and IL6), Th1 (IFN γ and TNF α) and Th2 (IL13 and IL4)
398 phenotype. The notable exception was lack of pathways associated with humoral adaptive
399 responses represented by B cells, plasma cells/plasma blasts and antibodies, which are hallmark
400 of MS.

401 While Th2 T cells are beneficial in acute experimental allergic encephalomyelitis models of MS,
402 Th2 inflammation may also cause fibrosis, which we found strongly linked to MS progression.
403 IL11, another upstream regulator identified in our analyses, is almost exclusively expressed in
404 fibroblasts and linked to many fibrotic conditions (31).

405 Fibrosis is associated with EMT, a process in which epithelial cells lose their tight-
406 junctions/desmosome-mediated association with basal membranes and with each other.
407 Dislodged epithelia differentiate into myofibroblasts, gaining invasive properties. Many
408 signaling pathways, e.g., eGFR, WNT/beta-catenin, NOTCH, PI3K/AKT, NF κ B, and hypoxia,
409 induce EMT. We show that activation of upstream regulators of these pathways increases with
410 MS progression. Although fibrosis is an end result of many chronic inflammatory processes,
411 literature search demonstrates that its intrathecal activation has not been previously recognized in

412 MS. If novel anti-fibrotic agents cross BBB, they might be tested as adjunctive treatments for
413 (some) MS patients, although we acknowledge that fibrosis was more strongly associated with
414 MS progression than MS severity, suggesting that it may represent an epiphenomenon.

415 Another novel finding is that different biological processes underlie predominant involvement of
416 brain versus SC by MS: neuroinflammation was associated with predominant involvement of
417 brain and fibrosis with SC-predominant MS. Of course, we cannot determine which drives
418 which: whether CNS location modulates phenotype and outcome of the inflammatory infiltrate,
419 or whether propensity to different phenotype/outcome of inflammation determines location of
420 CNS injury. Only future studies, ideally linked to genetics, might answer this emerging question.

421 Perhaps the most important finding, with direct relevance for future drug development, is our
422 identification of pathways that correlate with MS severity. While neuroinflammatory processes
423 dominated this analysis as well, there were some notable differences that may provide insight
424 into MS disease mechanisms. We mentioned previously that pathways linked to activation of the
425 humoral arm of adaptive immunity were not associated with MS progression but were associated
426 with MS severity. Indeed, these pathways correlated with IgG index, which is elevated in vast
427 majority of MS patients from the onset of MS till its end. Likewise, while biomarkers released
428 by all T cell phenotypes were linked to MS progression, Th17 pathways were more strongly
429 associated with MS severity than MS progression. Equally, activation of innate immunity was
430 linked to both MS progression and MS severity, but pathways linked to MS severity were
431 enriched for effector mechanisms that mediate tissue damage, such as NK cells, generation of
432 NO and ROS and pyroptosis. Three pathways related to viral infections were also exclusively
433 associated with MS severity, but not MS progression.

434 If we were to integrate the gained knowledge into a single hypothesis, it would be that EBV
435 reactivation of latently infected B cells, perhaps with lytic infection of some CNS epithelial cells,
436 not only triggers MS, but continues fueling the compartmentalized inflammation. Resulting
437 pyroptosis, identified in MS lesions (32), may be an important mechanism of CNS cells death in
438 MS. Indeed, MS-derived EBV-infected CSF B cells have higher lymphangiogenic potential
439 compared to controls (33) and therefore may contribute to formation of tertiary lymphoid
440 follicles, a hallmark of compartmentalized inflammation in MS (34). However, EBV presence in
441 MS CNS remains controversial (35, 36), requiring further research to investigate the
442 hypothesized link between EBV and MS progression.

443 Current study has following limitations: 1. The IPA knowledge base and therefore our pathway
444 analyses integrate knowledge from varied sources such as human and animal in-vitro and in-vivo
445 data derived from different biological fluids or organs, with human CNS being likely under-
446 represented. One may wonder how relevant our conclusions are to human CNS tissue.

447 Reassuringly, processes our pipeline linked to MS progression overlap greatly with processes
448 seen in postmortem MS CNS, such as hypoxia, activation of clotting cascade, compartmentalized
449 inflammation, and microglia/macrophage activation with generation of NO and ROS (4, 37-39).

450 Additionally, patient-specific pathway scores we generated using bioinformatics pipeline
451 correlated highly with relevant validated biomarkers: e.g. BAFF/APRIL signaling pathway

452 correlating with IgG index. Nevertheless, we acknowledge that some recently discovered
453 biological processes linked to MS severity, such as toxic astrogliosis (40-42), are not yet

454 annotated in IPA and were missed. 2. Although subtracting effects of physiological aging and

455 sexual dimorphism on CSF biomarkers helped to identify MS-related processes, it likely under-

456 estimated effect sizes with which CSF biomarkers can predict MS progression and severity

457 outcomes. This is because both age and sex affect MS progression and MS severity. 3. We did
458 not study effect of additional confounding factors that affect neurological disability, such as
459 cardiovascular risk factors. Incorporating such covariates may further strengthen models, but this
460 will require detailed measurement of comorbidities and multi-organ functions and likely larger
461 cohorts. 4. Some of the outcomes we used for modeling have not been extensively validated and
462 are not used outside of our group, making it hard for readers to interpret. We already explained
463 why such novel outcomes were necessary for successful modeling. Provided correlation matrices
464 and recalibration of CSF biomarker-based models to predict traditional, well-known outcomes in
465 the independent validation cohort successfully mitigated this limitation. 5. Correlation is not
466 causation. Only successful interventional clinical trials can validate causality of disease
467 mechanisms; however, such trials need a solid rationale. We believe this study provides such
468 rationale. By applying creative analysis to differentiate likely candidate mechanisms from
469 epiphenomena our study help prioritizing targets in future drug development.

470 Current study showcases that CSF biomarkers can quantify diverse molecular processes in living
471 humans from very limited CSF sample and repeatedly. Such longitudinal measurements of
472 cardiovascular risk factors were instrumental in determining their likely causality, linking their
473 dose/exposure interactions to morbidity/mortality outcomes (43). Even though the proof of
474 causality came from successful clinical trials (as it always must), measurements of biomarkers
475 like LDL cholesterol selected trial population, measured pharmacodynamic effects and guided
476 dose selections. Collectively, these studies led to understanding that multiple processes cause
477 cardiovascular diseases, that they are not uniformly distributed among subjects, and if present,
478 they must all be therapeutically inhibited by patient-specific, biomarker-guided polypharmacy
479 regimen to effectively limit cardiovascular morbidity/mortality. We see strong parallels with our

480 results: analogously to transformative pathology study revealing heterogeneity in the
481 composition of acute MS lesions (44), we observed intra-individual heterogeneity in the non-
482 lesional candidate pathogenic mechanisms. The patient-specific candidate causal mechanisms
483 cannot be predicted by clinical classification of MS subtypes, they require CSF biomarker
484 measurements. Because other than CNS-related pathways, like synaptogenesis, all remaining
485 candidate causal mechanisms we identified are not organ specific, only CSF biomarkers can
486 unequivocally link them to CNS tissue. While the assay we used is not clinical, we hope this
487 study will spur interest in developing clinical-grade assays to comprehensively measure CSF
488 biomarkers. Clinical-grade measurements of CSF biomarkers might greatly facilitate drug
489 development for CNS diseases and eventually guide patient-specific polypharmacy regimen we
490 take for granted in contemporary management of cardiovascular diseases, into neurological
491 practice.
492

493 **MATERIALS AND METHODS**

494 **Study design**

495 This was a retrospective analysis of prospectively acquired cohort with details described in
496 Figure 1, Table 1, and Supplemental Table 1.

497 **Subjects**

498 A total of 394 MS patients (124 with PPMS, 179 with RRMS, and 91 with SPMS) and 45 HV
499 were prospectively enrolled between January 1999 and December 2018 into natural history
500 protocol “Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central
501 Nervous System” (Clinicaltrials.gov identifier NCT00794352); samples collected before 2009
502 were part of the “NIB Repository Protocol” (10-N-021). The protocol recruited patients with
503 known or suspected diagnosis of MS. A thorough diagnostic workup included full neurological
504 exam, MRI of the brain, functional tests (e.g., T25FW, nine-hole peg test [9HPT], SDMT,
505 PASAT) and laboratory tests of blood and CSF. Each patient was followed for minimum of 1
506 year (with optional follow-up LP). Seventy-eight percent of CSF samples were collected in
507 untreated stage. The inclusion criteria for HV cohort were between ages 18–75, lack of
508 neurological diagnosis or systemic disease that would influence neurological functions or brain
509 MRI and with vital signs in the normal range during the initial screening. The demographic data
510 of all subjects are detailed in Table 1, demographic data for MS subtypes are in Supplemental
511 Table 1.

512 **Sample processing**

513 CSF was collected on ice and processed according to a written standard operating procedure by
514 investigators blinded to diagnoses, clinical, and imaging outcomes. Aliquots were assigned

515 alphanumeric identifiers and centrifuged for 10 minutes at 300g at 4°C within 30 minutes of
516 collection. The pelleted CSF cells were processed by flow cytometry and the cell-free
517 supernatants were aliquoted and stored in polypropylene tubes at -80°C.

518 **MRI imaging**

519 MRI of the brain was generated on 1.5T and 3T scanners (General Electric & Siemens). T1
520 magnetization-prepared rapid gradient echo (MPRAGE) and T2-weighted 3D fluid attenuation
521 inversion recovery (3D FLAIR) sequences were obtained. Assessment of contrast enhancement
522 was performed using postcontrast (gadopentetate dimeglumine at 0.1 mmol/kg) T1-weighted and
523 postcontrast FLAIR images. The number of CELs was recorded in the research database. The
524 MRI protocol extended caudally to C5 level to allow analysis of upper cervical SC.

525 The volumetric analysis was performed using LesionTOADS volume segmentation algorithm
526 performed on QMENTA imaging platform (www.qmenta.com). The details of the analyses have
527 been described (45). BPF_r was calculated as a ratio between the total brain volume and
528 intracranial cavity volume. Upper cervical SC cross-sectional area (C1–C2) was calculated from
529 brain MRI images using Spinal Cord Toolbox (46). The investigators generating volumetric MRI
530 data were blinded to diagnostic codes, clinical outcomes or any laboratory outcomes.

531 **Clinical outcomes**

532 Neurological exams have been recorded directly (after 9/2017) or transcribed retrospectively
533 from structured medical records neurological examination form (before 9/2017) into NeurEx™
534 App (47) that automatically calculates traditional MS disability outcomes –EDSS (9), SNRS
535 (19), Hauser AI (21), IPEC disability scale (20). CombiWISE was calculated from EDSS, SNRS,
536 T25FW and nondominant hand of 9HPT, as described (14).

537 EDSS-based MS severity outcomes –MSSS (48), ARMSS (10), and MS-DSS (17) - were
538 calculated as described.

539 Generation of novel outcomes for this study are described in the Results section.

540 **Flow cytometry**

541 Fresh CSF cells collected from ~20cc of CSF were resuspended in 200ul of X-VIVO™ 15
542 (Lonza, REF: 04-418Q) on ice. A minimum of 2,000 cells were stained with a 12-color antibody
543 panel, analyzed by BD Bioscience LSR II flow cytometer, and gated using BD FACSDiva
544 software as described (49). The results have been prospectively entered into the research
545 database, quality-controlled and locked from further changes. The database automatically
546 calculated proportions (percentages) of different cell populations based on total cell number.

547 **CSF immunoassays**

548 CSF levels of NFL, CD27, CHI3L1, and SERPINA3 were measured by personnel blinded to
549 diagnostic, clinical and MRI outcomes. NFL and SERPINA3 were quantified using
550 spectrophotometric assays by UmanDiagnostics (catalog# 10-7002) and RayBiotech (catalog#
551 ELH-SERPINA3-1) respectively. CHI3L1 and CD27 were quantified via homebrew assays on
552 MSD-ECL platform using antibodies from R&D systems (catalog# DY2599) and Sanquin
553 (catalog# M1960) respectively. Details of the assays have been published previously (50).

554 **SOMAScan analysis**

555 Total of 1,042 unique CSF samples marked with alphanumeric coded were analyzed by
556 SOMAScan (Somalogic Inc, Boulder, CO, USA). Samples representing different diagnostic
557 groups were interspersed between individual 96-well plates, while longitudinal samples of a
558 single patient were kept within the same plate. SOMAScan assay measured relative fluorescent

559 units (RFU) of 5,034 DNA aptamers, called SOMAmers. The raw RFUs have been
560 mathematically processed to normalize the hybridization signal within each plate, and to
561 calibrate the signal across different plates, using control samples embedded within each plate.

562 **Adjustment for physiological aging and sexual dimorphism**

563 To regress out the effect of natural aging and sexual dimorphism for each SOMAmer the
564 normalized and calibrated RFUs were log-transformed and a linear regression model using age
565 and sex as two independent variables was generated in the HV cohort. The prediction of this
566 model was then subtracted from each sample, resulting in age- and sex-adjusted RFUs, with
567 mean of HV cohort of zero. For further analyses, the SOMAmer levels of MS patients were also
568 standardized to HV, resulting in HV mean of zero and HV SD of one.

569 **Ingenuity Pathway Analysis (IPA[®])**

570 To identify biological processes associated with MS outcomes, first, we performed a univariate
571 correlation between outcomes (T2LL, BD, CombiWISE, SC disability for MS progression and
572 BD severity, CombiWISE severity, SC severity, MS-DSS for MS severity) and age-/sex-adjusted
573 SOMAmers in the MS cohort. For statistically significant correlations (FDR-adjusted $p < 0.05$)
574 the Spearman Rho coefficients were submitted into IPA[®] and a Core Expression Analysis was
575 performed using “Expr Other” as a measurement type. The identified Canonical pathways,
576 Upstream regulators, and Causal networks were exported for each outcome and merged using
577 RStudio software Version 1.1.463 (R version 4.0.2) (51). A sum of z-scores and sum of $-\log_{10} p$ -
578 value were calculated for each pathway/upstream regulators/causal network across the four MS
579 progression and four MS severity outcomes.

580 For longitudinal changes, pairs of untreated CSF samples were identified maximizing the length
581 of follow-up. The differences in age-/sex-adjusted SOMAmer levels between last and first LP
582 were calculated for each patient. Paired one-sample two-sided Wilcoxon test identified
583 statistically significant changes (rejecting the null hypothesis of no change over time) after the
584 FDR adjustment for multiple comparisons. The median values of significant longitudinal
585 changes were then submitted to IPA[®] followed by the same analysis as described above.

586 MS-specific differences were calculated between HV cohort and MS cohort represented by first
587 LP per patient. The median levels of SOMAmers in the HV cohort were subtracted from median
588 levels of MS patients and unpaired two-sample two-sided Wilcoxon test was used to identify
589 statistically significant differences between MS and HV that were again analyzed by IPA[®] as
590 described above.

591 To identify biology that differentiates brain vs SC damage, we generated two cohorts of
592 propensity score matched samples: 1) Linear regression model between BD and CombiWISE
593 identified CombiWISE residuals—patients with proportionally higher and lower measured
594 CombiWISE than what would be predicted by their BD levels. Patients with CombiWISE
595 residuals within the interquartile range (IQR) of the data distribution were removed and
596 remaining patients with residuals less than Q1 and greater than Q3 were matched for BD levels
597 using propensity score matching (matchit function with “full” method; “MatchIt” R package
598 (52)). Differences in age-/sex-adjusted SOMAmers between matched samples were assessed by
599 paired two-sample two-sided Wilcoxon test after FDR-adjustment for multiple comparison. The
600 medians of differences for identified SOMAmers were analyzed by IPA[®]. 2) The same workflow
601 was applied to comparison between BD and CombiWISE, by regressing out disability measured
602 by CombiWISE and calculating BD residuals.

603 To identify differences in biology representing MS progression vs severity, the canonical
604 pathways z -scores and $-\log_{10} p$ -values were summed up across the four MS progression and four
605 MS severity outcomes. Differentially activated pathways were identified as those with absolute
606 sum of z -scores greater than 4, sum of $-\log_{10} p$ -value greater than 1.33 and the difference
607 between sum of z -scores for severity and sum of z -scores for progression greater than 2.

608 To calculate patient-specific pathways activation scores, the details for each canonical pathway
609 were downloaded from IPA[®] and intersected with proteins measured by SOMAscan. The HV-
610 normalized SOMAmer values corresponding to pathway components and measured at first
611 untreated CSF sample were averaged, after adjustment for their predicted effect on pathway
612 activation (e.g., adding scores of analytes predicted to activate the pathway and subtracting
613 scores of analytes predicted to inhibit the pathway). The patient-specific pathway scores were
614 analyzed by unsupervised hierarchal clustering using the “ward.D” clustering as part of the
615 “Pheatmap” R package (<https://CRAN.R-project.org/package=pheatmap>).

616 **Machine learning models**

617 To formally test whether our training cohort was sufficiently powered to find optimal solution
618 with numbers of predictors exceeding numbers of subjects, two sets of predictors were
619 considered, 5,034 age- and sex-adjusted single SOMAmers, and 12.9 million age- and sex-
620 adjusted SOMAmer ratios. Two modeling strategies were tested: EN (linear modeling strategy
621 that can handle collinearity between some SOMAmers) and RF (a tree-based algorithm capable
622 of capturing nonlinear relationships and disease heterogeneity). Models were generated in
623 randomly split two-thirds of MS patients that constituted the “training cohort” and the
624 performance of the models was tested in the remaining one-third of the MS patients that
625 constituted the “validation cohort”. The models were generated either using all available LPs per

626 patient (i.e., including CSF from treated patients) in the training cohort or using only the first LP
627 per patient. The validation was performed in both cases using only the first LP per patient in the
628 validation cohort.

629 The EN models on single SOMAmers were generated using glmnet R package (53) and the EN
630 models on SOMAmer ratios utilized biglasso R package (54); the RF modeling used ranger R
631 package (55). For RF models an iterative process of dimension reduction was performed, as
632 described (56), by removing bottom 10% of variables with the least variable importance
633 measured based on node impurity. The process was repeated until root mean square error
634 (RMSE) stabilized or increased. The OOB error was assessed for each final RF model. Spearman
635 correlation coefficient (Rho), coefficient of determination (R^2), CCC, and RMSE were calculated
636 to assess the models' performance.

637 **Statistics**

638 All data were analyzed using R Studio software (details of packages used for analyses are
639 mentioned above). Statistical analyses were performed using one- or two-sample two-sided
640 Wilcoxon tests or t-test. FDR-adjustment was used to correct for multiple comparisons. More
641 details on statistical methods used are described above.

642 **Study approval**

643 Clini

644 **Abbreviations**

645 9HPT – nine-hole peg test

646 AI – ambulation index

647 ARMSS – age-related multiple sclerosis severity

648 BBB – blood-brain barrier

649 BD – brain damage

650 BPFr – brain parenchymal fraction

651 CCC – concordance correlation coefficient

652 CEL – contrast-enhancing lesion

653 CombiWISE – combinatorial weight-adjusted disability score

654 CNS – central nervous system

655 CSF – cerebrospinal fluid

656 DC – dendritic cell

657 EAE – experimental autoimmune encephalomyelitis

658 EBV – Epstein-Barr virus

659 EDSS – expanded disability status scale

660 EMT – epithelial-mesenchymal transition

661 EN – elastic net

662 FDR – false discovery rate

- 663 FLAIR - fluid attenuation inversion recovery
- 664 HV – healthy volunteer
- 665 IPA – Ingenuity Pathway Analysis
- 666 IPEC - Instituto de Pesquisa Clinica Evandro Chagas
- 667 IQR – interquartile range
- 668 lncRNA – long non-coding RNA
- 669 LP – lumbar puncture
- 670 MPRAGE - magnetization-prepared rapid gradient echo
- 671 MRI – magnetic resonance imaging
- 672 MS – multiple sclerosis
- 673 MS-DSS – multiple sclerosis disease severity scale
- 674 MSSS – multiple sclerosis severity score
- 675 NIH – National Institutes of Health
- 676 NK cell – natural killer cell
- 677 NO – nitric oxide
- 678 OOB – out-of-bag
- 679 PASAT – paced auditory serial addition test
- 680 PIRA – progression independent of relapse activity
- 681 PPMS – primary progressive multiple sclerosis

- 682 PMS – progressive multiple sclerosis
- 683 PRR – patter-recognition receptors
- 684 RF – random forest
- 685 RFU – relative fluorescent units
- 686 RMSE - root mean square error
- 687 ROS – reactive oxygen species
- 688 RRMS – relapsing-remitting multiple sclerosis
- 689 SC – spinal cord
- 690 SDMT – symbol-digit modalities test
- 691 SNRS – Scripps neurological rating scale
- 692 SPMS – secondary progressive multiple sclerosis
- 693 T25FW – timed 25-foot walk
- 694 T2LL – T2 lesion load
- 695

696 **List of Supplementary Materials**

697 Supplementary results

698 Supplemental Figure 1

699 Supplemental Figure 2

700 Supplemental Figure 3

701 Supplemental Figure 4

702 Supplemental Figure 5

703 Supplemental Figure 6

704 Supplemental Table 1

705 Supplemental Table 2

706 Supplemental Table 3

707 Supplemental Table 4

708 Supplemental Table 5

709 **Figure legends**

710 **Figure 1. Study design.** Patients with suspected or known multiple sclerosis (MS) diagnosis
711 were enrolled into natural history protocol that collects standardized clinical, functional and
712 brain imaging outcomes. Healthy volunteers (HV) undergo identical procedures. All subjects
713 have cerebrospinal fluid (CSF) collection at protocol entry with optional follow-up LPs. Clinical
714 CSF biomarkers are assessed by NIH clinical laboratory, while cellular CSF composition is
715 analyzed by flow cytometry prospectively. CSF proteins were generated from cryopreserved
716 coded samples by DNA-aptamer-based assay (SOMAScan), and in-house immunoassays (i.e.,
717 NFL, sCD27, CHIT3L1, and SERPINA3). CSF samples from HV were used to regress out
718 effects of natural aging and sexual dimorphism on CSF proteins. Age- and sex-adjusted
719 biomarkers were used for all downstream analyses. To generate nine CSF biomarker-based
720 models of MS outcomes, the MS patients were randomized into training and validation cohort. In
721 the training cohort, the outcomes were modeled using elastic net (EN) and random forest (RF)
722 algorithms using single SOMAmers and SOMAmer ratios as predictors. An optimization
723 pipeline on High Performance Computing cluster Biowulf generated final models. Appropriate
724 models were recalibrated in the training cohort to predict widely used outcomes of MS disability
725 (EDSS and SDMT) and severity (ARMSS). The models' performance was evaluated in the
726 independent validation cohort. Created with BioRender.com

727

728 **Figure 2. Development of novel, optimized outcomes.** (A) Changes in MS disease
729 characteristics over time. New MS lesions (yellow dotted line) start forming at MS onset and
730 peak after several years, declining even in untreated patients. Each new lesion contributes to total
731 lesion volume (purple dashed line) that remains relatively stable after focal lesions stop forming.

732 The level of MS disability and CNS tissue destruction, collectively called: MS progression
733 (purple solid line) increases steadily over the disease course. The inserts show MS patients
734 longitudinal data for two MS progression outcomes brain damage [BD] and CombiWISE,
735 demonstrating measurable linear progression slopes for both. Cross-sectional MS severity
736 outcomes (blue curly bracket) differentiate subjects who accumulated more (red) from those who
737 accumulated less (green) MS disability and CNS tissue damage in every age category. **(B)** BD
738 outcome was generated as the first component of the principal component analysis of brain
739 parenchymal fraction (BPFr derived from volumetric brain MRI analyses, x-axis) and cognitive
740 test Symbol-digit modalities test (SDMT, y-axis). The BD outcome correlates strongly with its
741 components (plots on the right). **(C)** Combinatorial Weight-adjusted Disability Scale
742 (CombiWISE) is a linear combination of four disability scores (the red triangle shows decreasing
743 weights of contributing scales), and it correlates strongly with traditional MS disability scales
744 EDSS and T25FW (plots on the right). **(D)** Spinal cord (SC) disability outcome represents
745 residuals of the linear regression model between CombiWISE (y-axis) and BD (x-axis). For
746 subjects with comparable BD positive residuals (shades of orange) differentiate subjects who
747 have proportionally more physical disability from those who have less physical disability
748 (negative residuals; shades of blue). MRI images on the right illustrate examples of patients with
749 (1) high SC disability (low level of brain atrophy and high level of SC atrophy), and (2) low SC
750 disability (unremarkable cervical SC and high level of brain atrophy). **(E)** Three novel outcomes
751 of MS severity were generated as age residuals of corresponding MS disability outcomes. The
752 examples of residuals are depicted as blue double-headed lines, the levels of MS severity are
753 shown in shades of green and red. **(H)** Multiple Sclerosis Disease Severity Scale (MS-DSS) is a
754 machine learning-derived outcome that utilizes a combination of clinical, imaging, therapy, and

755 demographic predictors, with their relative influence in MS-DSS represented by bar chart. MS-
756 DSS correlates strongly with traditional, EDSS-based MS severity scales: ARMSS and MSSS.

757

758 **Figure 3. Biology of natural history of MS.** (A) Correlation matrix between traditional MS
759 progression outcomes (in blue) and optimized MS progression outcomes (in black). SNRS,
760 SDMT, and PASAT scales (*) were inverted to retain the same directionality of all scores.
761 Spearman correlation coefficients are displayed, their font size corresponds to $-\log_{10} p$ -value. (B)
762 26 canonical pathways were identified in the cross-sectional MS cohort (left plot) based on
763 correlations with 4 MS progression outcomes. The effect sizes for individual pathways are
764 shown as sum of z -scores horizontal bars, where red represent predicted activation and blue
765 predicted inhibition of pathways with MS progression. The corresponding sum of $-\log_{10} p$ -value
766 are depicted as connected black dots. Same pathways were significantly changed in longitudinal
767 MS samples (middle plot; comparing first and last LP for each subject) and differentiated MS
768 from HV (right plot) with identical directionality (C) Examples of longitudinal patient-level
769 pathway scores (see Methods) of two predicted activated pathways, pulmonary fibrosis (top
770 plots) and HIF1 α signaling (bottom plots), showing statistically significant increase over time.
771 (D) A selection of upstream regulators and (E) causal networks associated with MS progression
772 are displayed with sum of z -score across the four progression outcomes on x-axis and sum of -
773 $\log_{10} p$ -value on the y-axis. The color of each point demonstrates the molecule type for identified
774 features.

775

776 **Figure 4. Biology of MS-related brain vs spinal cord damage.** (A) To separate MS patients
777 with predominant brain versus (SC) disease, we calculated SC disability as the residuals (green

778 lines) of the linear regression model between BD and CombiWISE. Residuals within
779 interquartile range (IQR, gray points) were removed, and the groups of patients with residuals
780 below the 1st quartile (Q1, dark blue points) and above the 3rd quartile (Q3, orange points) were
781 paired using propensity score matching on BD outcome. **(B)** Left plot: To prove that SC
782 disability reflects SC damage, we correlated it (y-axis) with upper cervical SC area measured by
783 MRI at C1-C2 level (x-axis) in the MS cohort. Right plot: MS patients with low SC disability
784 (Q1; dark blue) had significantly greater cervical SC volume than patients with high SC
785 disability (Q3; orange). **(C)** Statistically significant differences between Q1 and Q3 patients
786 identified 22 pathways significantly activated (red horizontal bars) or inhibited (blue horizontal
787 bars) when comparing patients with predominant SC (left plot) versus brain (right plot)
788 involvement. Horizontal bars with light blue or light red color didn't reach the significant z -score
789 cut-off (depicted as vertical dashed lines). The FDR-adjusted $-\log_{10} p$ -values for all pathways are
790 illustrated by green connected dots. **(D)** In sensitivity analyses the 22 pathways discovered in
791 panel **C** were also identified by comparing BD z -scores (x-axis) and CombiWISE z -scores (y-
792 axis). Top plot shows that pathways 1–13 activated (above the purple 1:1 line) in patients with
793 proportionally increased CombiWISE. Conversely, pathways 14–22 were activated in MS
794 patients with proportionally higher BD outcome (bottom plot).

795
796 **Figure 5. Biology of MS severity.** **(A)** Correlation matrix of traditional EDSS-based MS
797 severity outcomes (ARMSS and MSSS) and optimized MS severity outcomes used in this study.
798 Spearman correlation coefficients are displayed, the font size corresponds to the $-\log_{10}(p\text{-value})$.
799 **(B)** Flowchart of pathway identification: IPA-identified pathways for four progression outcomes
800 (blue) and four severity outcomes (red) were merged and the sum of z -scores and sum of $-\log_{10}$

801 p -value were calculated for each pathway. Pathways that differentiate MS severity from MS
802 progression had to fulfill the three displayed pathway selection criteria. (C) 25 pathways more
803 strongly (and significantly) associated with MS severity than MS progression outcomes. The
804 sum of z -scores is displayed as length of the horizontal bar (positive for activation, negative for
805 inhibition), the shades of blue and red fill illustrate difference between sum of z -scores for
806 severity and progression outcomes. Sum of $-\log_{10} p$ -value is displayed as green connected dots.
807 (D) We calculated patient-specific activation scores for selected pathways (see Methods) for
808 untreated MS patients at first LP. Unsupervised algorithm clustered patients (columns) into 4
809 clusters, and 25 pathways from (C) into 4 clusters (lines). Patient clusters differed in the level of
810 activation of B cell/plasma cell-activation pathway (orange), CNS cluster (blue),
811 coagulation/antioxidant cluster (green), and inflammation cluster (red). The numbers and colors
812 of individual pathways are identical in panels C and D. Additional outcomes/biomarkers are
813 displayed above the heatmap, illustrating distribution of age, diagnoses, disability, and severity
814 outcomes, as well as broadly accepted biomarkers of intrathecal inflammation sCD27 and IgG
815 index. Two plots on the bottom illustrate strong correlation between activation score for pathway
816 9 – BAFF/APRIL signaling and two biomarkers of intrathecal inflammation – IgG Index (left)
817 and CSF levels of sCD27 (right).

818

819 **Figure 6. CSF biomarker-based models of MS outcomes.** (A) In the training cohort (orange
820 box), two parallel modeling approaches were followed – using 5,034 SOMAmers (blue) or 12.9
821 million of SOMAmer ratios (red) as predictors to model 9 already introduced MS outcomes.
822 Each outcome was modeled using two algorithms – elastic net (EN) linear regression and tree-
823 based algorithm random forest (RF). For RF models, out-of-bag (OOB) predictions were

824 evaluated as more realistic estimate of effect sizes from training cohort data. The generated
825 models were then tested in the independent validation cohort (green box) that did not contribute,
826 in any way, to model generation. **(B)** A comparison of models' performance based on Spearman
827 Rho in training (circles), OOB (squares), and validation (diamonds) cohorts. The EN models are
828 illustrated by dotted lines connecting training and validation cohort sets, while RF models are
829 connected with solid lines. Models built with single SOMAmers as predictors are in blue, models
830 generated from SOMAmer ratios are shown in red. The size of the points represents the number
831 of predictors retained in the final model, the fill of the datapoints illustrates $-\log_{10} p$ -value. Two
832 RF models of SC severity did not validate (n.s.). **(C)** To compare effect sizes of CSF-based
833 models with published literature, we recalibrated appropriate models (i.e., CombiWISE for
834 EDSS and CombiWISE severity for ARMSS) based on strong correlations between CombiWISE
835 and EDSS and CombiWISE severity and ARMSS in the MS training cohort. Specifically,
836 SOMAmer-predicted CombiWISE was used to generate a simple linear regression model of
837 measured EDSS in the training cohort (top plot). The regression equation was then used in the
838 validation cohort to predict EDSS (second plot from the top). The blue line represents 1:1 line.
839 Analogous method was used for predicting ARMSS (bottom two plots).

840 **Table 1. Demographic data**

	HV	MS training	MS validation
Number of samples	71	647	324
Number of subjects	45	252	142
Sex (% female)	48.9	60.3	57.7
Age at first LP (min-max)	19.4 - 71.3	18 - 68.2	18.3 - 74.7
Age at first LP (mean ± sd)	37.7 ± 13.4	47 ± 11.9	47.4 ± 12.5
Number samples/subject (min - max)	1 - 4	1 - 8	1 - 7
Number samples/subject (mean ± sd)	1.6 ± 0.9	2.6 ± 1.7	2.3 ± 1.6
years of follow-up (min - max)	0 - 4.7	0 - 15.7	0 - 19.8
years of follow-up (mean ± sd)	0.9 ± 1.4	2.6 ± 3.3	2.4 ± 3.5

841 min - minimum, max - maximum, sd - standard deviation, LP - lumbar puncture, HV – healthy volunteers, MS
 842 – multiple sclerosis

843 **Table 2. Summary of MS progression and MS severity outcomes used in the study**

Outcome	Acronym	MS process	Description	Reference
T2 lesion load	T2LL	Progression	Volume of T2 lesions generated from T1- and T2-weighted images using lesionTOADS algorithm integrated into Qmenta platform	(57)
Brain damage	BD	Progression	First component of the principal component analysis of brain parenchymal fraction (measured as percentage of brain parenchyma volume of the skull volume) and SDMT (measuring cognitive function)	This study
Combinatorial Weight-adjusted Disability Score	CombiWISE	Progression	Machine learning model that combines weighted disability scores: EDSS, SNRS, T25FW, and nondominant hand of the 9HPT	(14)
Spinal cord disability	SC disability	Progression	Residuals of the linear regression model between BD (measuring cognitive disability) and CombiWISE (measuring physical disability)	This study
Brain damage severity	BD severity	Severity	Age residuals of BD	This study
CombiWISE severity	CombiWISE severity	Severity	Age residuals of CombiWISE	This study
Spinal cord severity	SC severity	Severity	Age residuals of SC disability	This study
MS Disease Severity Scale	MS-DSS	Severity	Machine learning model that combines measured disability, therapy intervention, age, and MRI grading of the CNS destruction	(17)

844 References

- 845 1. Bjernevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high
846 prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science*. 2022;375(6578):296-301.
- 847 2. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA
848 deletions and neurodegeneration in multiple sclerosis. *Ann Neurol*. 2011;69(3):481-92.
- 849 3. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, and Nataf S. Meningeal T cells associate
850 with diffuse axonal loss in multiple sclerosis spinal cords. *Ann Neurol*. 2010;68(4):465-76.
- 851 4. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in
852 secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
853 *Brain*. 2007;130(Pt 4):1089-104.
- 854 5. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical
855 demyelination in early multiple sclerosis. *N Engl J Med*. 2011;365(23):2188-97.
- 856 6. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in
857 active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. *Brain*.
858 2012;135(Pt 3):886-99.
- 859 7. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within
860 axons in multiple sclerosis. *Brain*. 2009;132(Pt 5):1161-74.
- 861 8. Haider L, Fischer MT, Frischer JM, Bauer J, Hofberger R, Botond G, et al. Oxidative damage in multiple
862 sclerosis lesions. *Brain*. 2011;134(Pt 7):1914-24.
- 863 9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
864 *Neurology*. 1983;33(11):1444-52.
- 865 10. Manouchehrinia A, Westerlind H, Kingwell E, Zhu F, Carruthers R, Ramanujam R, et al. Age Related
866 Multiple Sclerosis Severity Score: Disability ranked by age. *Mult Scler*. 2017;23(14):1938-46.
- 867 11. Smith A. *Symbol digit modalities test*. Western psychological services Los Angeles; 1973.
- 868 12. Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, and Bielekova B. Meta-analysis of the Age-
869 Dependent Efficacy of Multiple Sclerosis Treatments. *Front Neurol*. 2017;8:577.
- 870 13. Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, et al. Defining secondary
871 progressive multiple sclerosis. *Brain*. 2016;139(Pt 9):2395-405.
- 872 14. Kosa P, Ghazali D, Tanigawa M, Barbour C, Cortese I, Kelley W, et al. Development of a Sensitive
873 Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment. *Front Neurol*.
874 2016;7:131.
- 875 15. Koch MW, Mostert J, Zhang Y, Wolinsky JS, Lublin FD, Strijbis E, et al. Association of Age With
876 Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. *Neurology*.
877 2021;97(13):e1334-e42.
- 878 16. Pham L, Harris T, Varosanec M, Morgan V, Kosa P, and Bielekova B. Smartphone-based symbol-digit
879 modalities test reliably captures brain damage in multiple sclerosis. *NPJ Digit Med*. 2021;4(1):36.
- 880 17. Weideman AM, Barbour C, Tapia-Maltos MA, Tran T, Jackson K, Kosa P, et al. New Multiple Sclerosis
881 Disease Severity Scale Predicts Future Accumulation of Disability. *Front Neurol*. 2017;8:598.
- 882 18. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. *Percept Mot*
883 *Skills*. 1977;44(2):367-73.
- 884 19. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, and Oldstone MB. A neurologic rating scale
885 (NRS) for use in multiple sclerosis. *Neurology*. 1984;34(10):1368-72.
- 886 20. Schmidt F, Oliveira AL, and Araujo A. Development and Validation of a Neurological Disability Scale for
887 Patients with HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): The IPEC-1
888 Scale (P03.258). *Neurology*. 2012;78(1 Supplement):P03.258-P03.
- 889 21. Hauser SL, Dawson DM, Lehigh JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression
890 in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous
891 cyclophosphamide, plasma exchange, and ACTH. *N Engl J Med*. 1983;308(4):173-80.
- 892 22. Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, et al. Insufficient disease inhibition by
893 intrathecal rituximab in progressive multiple sclerosis. *Ann Clin Transl Neurol*. 2016;3(3):166-79.
- 894 23. Kosa P, Wu T, Phillips J, Leinonen M, Masvekar R, Komori M, et al. Idefenone does not inhibit disability
895 progression in primary progressive MS. *Mult Scler Relat Disord*. 2020;45:102434.
- 896 24. Rothhammer V, and Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating
897 immune responses in health and disease. *Nat Rev Immunol*. 2019;19(3):184-97.

- 898 25. Peng B, Kong G, Yang C, and Ming Y. Erythropoietin and its derivatives: from tissue protection to
899 immune regulation. *Cell Death Dis.* 2020;11(2):79.
- 900 26. Kriegeskorte N, Simmons WK, Bellgowan PSF, and Baker CI. Circular analysis in systems neuroscience:
901 the dangers of double dipping. *Nature Neuroscience.* 2009;12(5):535-40.
- 902 27. Makin TR, and Orban de Xivry JJ. Ten common statistical mistakes to watch out for when writing or
903 reviewing a manuscript. *Elife.* 2019;8.
- 904 28. Liu J, Kelly E, and Bielekova B. Current Status and Future Opportunities in Modeling Clinical
905 Characteristics of Multiple Sclerosis. *Frontiers in Neurology.* 2022;13.
- 906 29. Thompson AJ, Carroll W, Ciccarelli O, Comi G, Cross A, Donnelly A, et al. Charting a global research
907 strategy for progressive MS-An international progressive MS Alliance proposal. *Mult Scler.* 2022;28(1):16-
908 28.
- 909 30. Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, et al. Multiple sclerosis
910 genomic map implicates peripheral immune cells and microglia in susceptibility. *Science.*
911 2019;365(6460):eaav7188.
- 912 31. Schafer S, Viswanathan S, Widjaja AA, Lim WW, Moreno-Moral A, DeLaughter DM, et al. IL-11 is a
913 crucial determinant of cardiovascular fibrosis. *Nature.* 2017;552(7683):110-5.
- 914 32. McKenzie BA, Mamik MK, Saito LB, Boghazian R, Monaco MC, Major EO, et al. Caspase-1 inhibition
915 prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. *Proc Natl Acad Sci*
916 *U S A.* 2018;115(26):E6065-E74.
- 917 33. Stein J, Xu Q, Jackson KC, Romm E, Wuest SC, Kosa P, et al. Intrathecal B Cells in MS Have
918 Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.
919 *Front Neurol.* 2018;9:554.
- 920 34. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A Gradient of neuronal
921 loss and meningeal inflammation in multiple sclerosis. *Ann Neurol.* 2010;68(4):477-93.
- 922 35. Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R, et al. B-cell enrichment and
923 Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. *J*
924 *Neuropathol Exp Neurol.* 2013;72(1):29-41.
- 925 36. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM, and NeuroproMiSe EBVWG. Epstein-Barr virus in
926 the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for
927 Brain Research of the Medical University of Vienna, Austria. *Brain.* 2011;134(Pt 9):2772-86.
- 928 37. van Olst L, Rodriguez-Mogeda C, Picon C, Kiljan S, James RE, Kamermans A, et al. Meningeal
929 inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially
930 associate with neurodegeneration. *Acta Neuropathol.* 2021;141(6):881-99.
- 931 38. Graumann U, Reynolds R, Steck AJ, and Schaeren-Wiemers N. Molecular changes in normal appearing
932 white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult.
933 *Brain Pathol.* 2003;13(4):554-73.
- 934 39. Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, et al. Quantitative susceptibility mapping
935 identifies inflammation in a subset of chronic multiple sclerosis lesions. *Brain.* 2019;142(1):133-45.
- 936 40. Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive
937 astrocytes are induced by activated microglia. *Nature.* 2017;541(7638):481-7.
- 938 41. Masvekar R, Kosa P, Barbour C, Milstein JL, and Bielekova B. Drug library screen identifies inhibitors of
939 toxic astrogliosis. *Mult Scler Relat Disord.* 2022;58:103499.
- 940 42. Masvekar R, Wu T, Kosa P, Barbour C, Fossati V, and Bielekova B. Cerebrospinal fluid biomarkers link
941 toxic astrogliosis and microglial activation to multiple sclerosis severity. *Mult Scler Relat Disord.*
942 2019;28:34-43.
- 943 43. Sniderman AD, Lawler PR, Williams K, Thanassoulis G, de Graaf J, and Furberg CD. The causal exposure
944 model of vascular disease. *Clin Sci (Lond).* 2012;122(8):369-73.
- 945 44. Hofberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V, Hochmeister S, et al. The pathology
946 of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte
947 glycoprotein autoantibody. *Acta Neuropathol.* 2020;139(5):875-92.
- 948 45. Kim Y, Varosanec M, Kosa P, and Bielekova B. Confounder-adjusted MRI-based predictors of multiple
949 sclerosis disability. *medRxiv.* 2022:2022.04.18.22273974.
- 950 46. De Leener B, Levy S, Dupont SM, Fonov VS, Stikov N, Louis Collins D, et al. SCT: Spinal Cord Toolbox,
951 an open-source software for processing spinal cord MRI data. *Neuroimage.* 2017;145(Pt A):24-43.

- 952 47. Kosa P, Barbour C, Wichman A, Sandford M, Greenwood M, and Bielekova B. NeurEx: digitalized
953 neurological examination offers a novel high-resolution disability scale. *Ann Clin Transl Neurol.*
954 2018;5(10):1241-9.
- 955 48. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis
956 Severity Score: using disability and disease duration to rate disease severity. *Neurology.* 2005;64(7):1144-
957 51.
- 958 49. Hannikainen PA, Kosa P, Barbour C, and Bielekova B. Extensive Healthy Donor Age/Gender Adjustments
959 and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping.
960 *Front Neurol.* 2020;11:565957.
- 961 50. Masvekar R, Phillips J, Komori M, Wu T, and Bielekova B. Cerebrospinal Fluid Biomarkers of Myeloid
962 and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity. *Front*
963 *Neurosci.* 2021;15:649876.
- 964 51. . R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
965 Computing. <https://www.R-project.org/>.
- 966 52. Ho DE, Imai K, King G, and Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal
967 Inference. . *Journal of Statistical Software.* 2011;42(8):1-28.
- 968 53. Friedman J, Hastie T, and Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate
969 Descent. *J Stat Softw.* 2010;33(1):1-22.
- 970 54. Zeng Y, and Breheny P. The biglasso Package: A Memory- and Computation-Efficient Solver for Lasso
971 Model Fitting with Big Data in R. *ArXiv e-prints.* 2017.
- 972 55. Wright M, and Ziegler A. ranger: A Fast Implementation of Random Forests for High Dimensional Data in
973 C++ and R. *Journal of Statistical Software.* 2017;77(1):1-17.
- 974 56. Jackson KC, Sun K, Barbour C, Hernandez D, Kosa P, Tanigawa M, et al. Genetic model of MS severity
975 predicts future accumulation of disability. *Ann Hum Genet.* 2020;84(1):1-10.
- 976 57. Shiee N, Bazin PL, Ozturk A, Reich DS, Calabresi PA, and Pham DL. A topology-preserving approach to
977 the segmentation of brain images with multiple sclerosis lesions. *Neuroimage.* 2010;49(2):1524-35.
978

979

980 **Acknowledgments:** This study was conducted as part of Cooperative Research and
981 Development Agreement between National Institutes of Health, Novartis, and Somalogic.
982 The content of this publication does not necessarily reflect the views or policies of the
983 Department of Health and Human Services, nor does mention of trade names, commercial
984 products, or organizations imply endorsement by the U.S. Government.
985 The authors would like to thank Yolanda L. Jones, NIH Library, for editing assistance.
986 This work utilized the computational resources of the NIH HPC Biowulf cluster
987 (<http://hpc.nih.gov>).

988
989 **Funding:** The research was supported by the Intramural Research Program of the National
990 Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This
991 project was also supported in part with federal funds from the National Cancer Institute, National
992 Institutes of Health, under Contract No. 75N910D00024, Task Order No. 75N91019F00130.

993
994 **Author contributions:**

995 Conceptualization: BB

996 Methodology: PK, KL, JW, CJL, BB

997 Software: PK, KL, JW, CJL

998 Formal analysis: PK, KL, JW

999 Investigation: PK, RM, YK, MV, BB

1000 Visualization: PK, BB

1001 Writing – original draft: PK, BB

1002 Writing – review & editing: PK, KL, JW, CJL, RM, YK, MV, LJ, BB

1003 Funding acquisition: BB, LJ

1004

1005 **Data and materials availability:** The datasets generated during and/or analyzed during the
1006 current study as well as the custom codes used to perform analyses will be available from the
1007 corresponding author after the manuscript has been peer-reviewed and published.






Figure 2: Development of granular outcomes


A Evolution of MS




B Brain Damage outcome




E MS severity outcomes



C Combinatorial Weigh-adjusted Disability Scale (CombiWISE) outcome



D Spinal cord (SC) disability outcome



H Multiple Sclerosis Disease Severity Scale (MS-DSS) outcome






Figure 3: Biology of natural history of MS


A Comparison of optimized MS progression outcomes with traditional MS disability scales




B Biological pathways associated with MS progression



C Longitudinal within-subject changes in activation of selected pathways



D Upstream regulators associated with MS progression



E Causal networks associated with MS progression






Figure 4: Biology of MS-related brain versus spinal cord damage


A Propensity score matching of samples based on disability outcomes



B CombiWISE residuals (Spinal cord disability) vs Spinal cord quantitative MRI



C Identified pathways based on significant differences in CSF Somamer levels between propensity score-matched groups of MS patients



D Identified pathways based on significant correlation between CSF Somamer levels and disability outcomes in all MS patients






Figure 5: Biology of MS severity


A Correlation matrix of MS severity outcomes



B Identification of pathways that differentiate MS severity from MS progression



C Identified pathways that differentiate MS progression from MS severity



D Clusters of untreated MS patients based on calculated Pathway scores






Figure 6: CSF biomarker-based models of MS disease characteristics

A Description of modeling strategy



B Comparisons of models' performance in training and validation cohorts



C Models' performance in predicting EDSS-based outcomes

